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ABSTRACT
Osteoporosis and cardiovascular (CV) disease share common risk factors and pathophysiology. Low bone mineral density (BMD) and
fractures appear to increase the risk for multiple CV diseases. Equally, prevalent CV disease appears to predispose to bone loss and
increase fracture rates. This relationship has naturally provoked the hypothesis that stopping bone lossmay result in some CV benefit.
Secondary analyses of safety and adverse event data from many randomized controlled trials (RCTs) have attempted to clarify this
putative association. Recently, the discontinuation of odanacatib (anti-cathepsin K monoclonal antibody) over stroke concerns and
the imbalance in ischemic events in romosozumab-treated (anti-sclerostin monoclonal antibody) women compared to
bisphosphonate-treated women, has provided further justification to better characterize potential CV benefits and harms of osteo-
porosis medications. This review delves into the seminal, and other major RCTs of osteoporosis medications and, using both pub-
lished data and additional information provided on trial registration pages, examines the evidence for CV safety and harms of
these medications. Accepted and emerging “off-target” effects are explored for validity, biological plausibility, and clinical impor-
tance. A brief research agenda is provided to stimulate the next wave of clinical development and CV understanding of osteoporosis
medications. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral
Research.
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Introduction
Osteoporosis is a systemic skeletal disorder characterized bythe loss of bonemass and deterioration in bonemicroarch-
itecture. These microstructural alterations combine to compro-
mise bone strength leading to skeletal fragility and increased
susceptibility of fracture.(1)
Fractures are a devastating outcome. Recovery from a fracture
is costly, takes manymonths and indeed some never truly recover
and lose independence. Indeed, mortality and the development
of comorbid disease, greatly increases after most types of frac-
tures but particularly hip fractures.(2) Recent health economic liter-
ature suggests that fractures pose a higher disease and cost
burden than most cancers (except lung cancer) but do not attract
as much public attention or institutional funding.(3)
Osteoporosis does not exist in isolation and indeedmay either
precede, develop concomitantly, or present secondary to other
comorbid diseases, analogous to how cardiovascular
(CV) disease may develop subsequently to type 2 diabetes melli-
tus. The association between CV disease and osteoporosis is of
profound importance because CV disease is overrepresented as
a cause of death in patients who have fractured; and fractures
are common in patients with known CV disease. Atherosclerosis
shares many risk factors with osteoporosis and is hypothesized
to establish in the decades of life when the net flux of available
calcium becomes deranged; “switching” from skeleton deposi-
tion to renal filtration and deposition in vessel walls and other
soft tissues.(4) Certainly, on a biological level, there appears to
be bidirectionality between bone and vascular disease.(5) Mech-
anisms underlying common aging, such as chronic inflammation
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as well as the decline in renal function predisposing to chronic
kidney disease (itself significantly effecting calcium and mineral
balance) are all thought to interact in the eventual co-
manifestation of osteoporosis and CV disease (Table 1).
Why Is It Important to Understand the
CV Benefits and Harms of Osteoporosis
Medications?
Given this context, there is a natural case suggesting that per-
haps improvements in skeletal health and fracture reduction
may lead to nonskeletal benefit, particularly where CV diseases
are concerned. Indeed, greater appreciation of the need for CV
disease management alongside fracture risk is warranted across
clinical specialties in order to do our best to improve the overall
outcomes experienced by patients. By understanding these non-
skeletal benefits and harms, we are doing our due diligence by
the patient because treatment uptake is affected markedly
by perceived risks of harmful albeit extremely rare side effects;
most recently regarding prescription of bisphosphonates
(BPs).(12) Understanding what treatments can accomplish, in
the widest possible sense, may impact the overall cost utility
landscape of such medications rather than a narrow focus on
bone health alone.
The scientific associations between the skeleton and heart
and vessels are strong but has not been translated into a clinical
message that bone protection may offer CV protection. For
example, in women who experience bone loss over time,
increases in systolic blood pressure were greatest in those who
experienced the greater reduction in bone density.(13) This
observation is not limited to women; data from the United States
show that in men (and women), CV disease is exhibited by those
who experience bone loss.(14) We have also begun to appreciate
the vascular-bone relationship, of how vascular disease can lead
to poorer skeletal outcome. In older women, atherosclerotic vas-
cular disease (ASVD) including vascular calcification is highly
prevalent and is associated with a higher risk of fractures.(15)
Though there is little awareness of this in daily clinical practice,
patients with underlying stroke or ischemic heart disease go on
to experience near double the number of fractures compared
to those who are disease-free.(9,16)
Finally, there is a regulatory rationale to understand the CV
effects of osteoporosis medications. The latest drugs off the
pipeline have been subjected to intense CV scrutiny, which is
of course appropriate given their prospective widespread use
in an older population. Indeed, the cathepsin K monoclonal anti-
body, odanacatib, was discontinued by the sponsor (Merck)
owing to concerns over increases rates of stroke compared to
placebo (1.7% [136/8043] versus 1.3% [104/8028]; hazard ratio
[HR]= 1.32; 95% confidence interval [CI], 1.02 to 1.70)(17) Further-
more, another monoclonal antibody, against sclerostin, romoso-
zumab, has been approved by the US Food and Drug
Administration (FDA) with a black-box warning for potential
increases in stroke and myocardial infarction owing to an imbal-
ance in adjudicated CV events in a large active-comparator
trial.(18) In other words, both the patients and the prescriber will
need to agree that any short-term increase in cardiovascular
morbidity is more than offset by long-term prevention of serious
fractures. This renewed interest in “off-target” effects, particu-
larly CV effects, of antifracture medications thus warrants further
exploration. This concept is already applied in the diabetes set-
ting where new glucose-lowering medications must also have
satisfactory results for both safety and efficacy in a CV outcome
trial.
What Is the Purpose and Scope of this Review?
The purpose of this review is to provide a comprehensive over-
view of the antifracture medication prescribing landscape and
examine the evidence for CV safety and harms of these medi-
cations. This review focuses on recent larger randomized con-
trolled trials (RCTs) with reference to key historical and
seminal trials in the development of some medications. Partic-
ular attention will be paid to studies conducted in postmeno-
pausal women and older men with osteoporosis/low BMD
and to nonhormonal treatments with proven antifracture effi-
cacy. Further, this review will focus on the meaningful collec-
tive outcome of the disease processes leading to CV events
as properly examining mechanistic pathways such as vascular
calcification is challenging in the setting of large RCTs. A previ-
ous review on this topic was framed as practical guide for the
new clinician.(19) This review is also aimed at the prescribing
clinician with the additional intention to provide a foundation
from which conversations about medication safety can be had
with patients. The CV safety of antifracture medications needs
to be explored in the context of patients with osteoporosis/low
BMD having a high underlying vascular disease burden and so
CV outcomes of osteoporosis RCTs may be confounded by
indication. Furthermore, this review is also aimed at the inter-
ested scientist, as we explore knowledge gaps in the bone-
CV field.
What Is “Accepted” to Be Known?
Mixed effects of BPs
No apparent mortality benefits
BPs are pyrophosphate analogues that have high affinity for
hydroxyapatite crystals in bone with a half-life of several years.
Table 1. Clinical Evidence for Bidirectionality Between Skeletal
Disease and Vascular Disease
Bone ! vascular Vascular ! bone
Prevalent vertebral fracture
predicted cardiac events in
older women ! HR = 2.9
(95% CI, 1.7–4.9)(6)
Diagnosis of atrial fibrillation
increased risk of hip fracture
! HR (men) = 1.97 (95% CI,
1.61–2.52) & HR
(women) = 2.08 (95% CI,
1.90–2.39)(7)
Whole-body BMD loss
predicted cardiac events in
older men ! HR = 1.78
(95% CI, 1.05–3.03)(8)
Stroke and MI increased the
risk of hip fracture ! HR
(stroke) = 3.86 (95% CI,
3.25–4.59) & ! HR
(MI) = 1.85 (95% CI, 1.54–
2.21)(9)
Total hip BMD predicted
incident heart failure in
black and non-black men!
HR = 0.66 (95% CI, 0.51–
0.85)(10)
Incident CV disease increased
the risk of vertebral fractures
compared to disease free!
HR = 1.47 (95% CI, 1.19–
1.81)(11)
Adapted from Rodriguez and colleagues.(5)
MI = myocardial infarction.
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BPs have a long history, with the first clinical use noted in
1969.(20) Their main effects appear to be on inhibiting resorption
by being taken up by osteoclasts and promoting their apoptosis,
thereby tipping the remodeling balance in favor of greater deposi-
tion to resorption. The idea that BPs could have some potential CV
effects stemmed from observations that etidronate (a first-genera-
tion, non–nitrogen-containing-BP) could delay the calcification pro-
cess in the vasculature and outside the skeleton.(21,22) Later
generation, nitrogen-containing BPs including oral alendronate,
risedronate, and intravenous (iv) zoledronic acid have been shown
to inhibit the farnesyl pyrophosphate synthase pathway in osteo-
clasts, which is a downstream step from the actions of
hydroxymethylglutaryl–coenzyme A (HMG-CoA) reductase inhibi-
tors (statins) in the production ofmevalonate in the cholesterol syn-
thesis pathway.(23) Given the robust literature surrounding the
cardioprotective and mortality benefits of inhibiting this pathway,
BPs too have been studied in this respect with mixed effects.
First, BPs appear to offer no mortality benefit as a class in
women and men.(24) In a meta-analysis of 21 trials of BPs
(n = 22,623 treated) versus placebo (n = 20,244), BP treatment
was associated with a nonsignificant 5% reduced relative risk
(RR) of overall mortality (event rates: 3.78% versus 4.35%; 95%
CI for RR, 0.86 to 1.04).(24) This finding was replicated in sensitiv-
ity analysis of zoledronic acid although with a larger effect size
of 22% (4.17% versus 4.07%; RR = 0.88; 95% CI, 0.68 to 1.13).
Analysis of alendronate-only studies (four trials) demonstrated
a null effect (1.55% versus 1.61%; RR = 1.00; 95% CI, 0.71 to
1.40). Interestingly, analysis of nitrogen-containing BPs (essen-
tially combining alendronate, risedronate, and zoledronic acid)
trended toward significance (2.98% versus 3.62%; RR = 0.90;
95% CI, 0.81 to 1.00). Furthermore, excluding zoledronic acid
from analysis of nitrogen-containing BPs marginally altered
the effect estimate (2.34% versus 2.90%; RR = 0.92; 95% CI,
0.79 to 1.07) suggestive of an oral BP–specific effect. These rates
and effect estimates are mentioned in detail as the moderate to
large effect sizes and upper limits of the confidence bounds
(1.00, 1.04, and 1.07) suggests that a clinically meaningful
reduction in mortality cannot be excluded given the weight of
evidence and results from observational cohorts. The meta-
analysis did not perform population specific sensitivity analyses
(men-only, hip fracture only, etc.) and thus these data indicate
there may yet exist a certain population with osteoporosis
who may experience a mortality benefit despite not necessarily
being prescribed for this effect. Given the high CV burden in
patients with osteoporosis, they may be interested in under-
standing these potential off-target effects despite clinical suspi-
cion that they are “too good to be true”.(25) Finally, there
appeared to be no mortality benefit for BPs in trials longer than
3 years, which was an interesting concept given the perceived
risk reduction seen in the Active-Controlled Fracture Study in
Postmenopausal WomenWith Osteoporosis at High Risk (ARCH)
trial occurred in the first 12 months(26) and risk reductions
appeared evident at approximately the 16-month mark of the
Health Outcomes and Reduced Incidence with Zoledronic Acid
Once Yearly–Recurrent Fracture Trial (HORIZON-RFT) trial by
Lyles and colleagues.(27) This would point to some transient
effect that could potentially be related to medication adher-
ence (observational data support this(28)) or represent a true,
underappreciated clinical effect mediated through the skele-
ton. There is a complete paucity of head-to-head studies exam-
ining this and there is limited data exploring these effects in
other agents(29,30) to elucidate if any potential mortality benefit
is mediated through skeletal effects.
Zoledronic acid may increase the risk of atrial fibrillation
Despite no apparent effect of BPs as a class on overall mortality,
cause-specific effects have been explored in greater detail. One
of the most well-described effects has been the apparent
increase in atrial fibrillation associated with iv zoledronic acid
(Table 2). This was first described in the HORIZON Pivotal Frac-
ture Trial by Black and colleagues from 2007.(31) This trial fol-
lowed on from the clinical development of alendronate as an
antifracture agent a decade earlier.(37) The aim of the HORIZON
study was to investigate if the more potent zoledronic acid had
similar effects to oral alendronate. The intravenous nature of
zoledronic acid was appealing to patients because it was
required only once yearly rather than daily or weekly as per the
oral formulation, which caused gastric problems. HORIZON
enrolled over 7700 women aged between 65 and 89 years and
randomly assigned to either 5 mg iv zoledronic acid or placebo
both with additional daily calcium (1000 to 1500 mg) and vita-
min D (400 to 1200 IU). There was an imbalance in overall
adverse events, mostly attributable to postinfusion symptoms.
Importantly, this seminal trial provided the first robust descrip-
tion for effects of BPs on atrial fibrillation. In those receiving iv
zoledronic acid, there were more atrial fibrillation events
(94/3862 [2.4%] versus 73/3852 [1.9%]; RR = 1.28; 95% CI, 0.94
to 1.73) that did not reach statistical significance but was signal
enough to prompt evaluation of serious atrial fibrillation. In this
instance, the imbalance reached statistical significance
(50/3862 [1.3%] versus 20/3852 [0.5%]; RR = 2.49; 95% CI, 1.48
to 4.18). This finding motivated an FDA review of oral alendro-
nate that showed 47 serious atrial fibrillation adverse events
(1.5%) in alendronate-treated and 31 (1.0%) in placebo-treated
during an average of 4 years (HR = 1.51; 95% CI, 0.97 to 2.40), a
finding that cannot rule out a clinically important effect. Reassur-
ingly, there was no increased risk of all atrial fibrillation adverse
events (81 events [2.5%] versus 71 events [2.2%]; HR = 1.14;
95% CI, 0.83 to 1.57).(38) The rationale for why BPs may provoke
arrhythmia is uncertain. Some preclinical studies point to poten-
tial disruption of calcium handling dynamics in cardiomyocytes
by BPs.(39) Other important triggers initiating atrial fibrillation
may arise from focally discharging cells located most commonly
at the pulmonary vein ostia. These foci may lead to frequent
atrial ectopy and paroxysms of atrial fibrillation. This effect is par-
ticularly relevant to the iv administration, which is clouded by flu-
like symptoms postinjection.(40) BPs can also stimulate release of
inflammatory cytokines, which are implicated in increasing the
risk of atrial fibrillation but through mechanisms that have not
been fully elucidated.(41,42) These data were enough to include
in atrial fibrillation as a rare but of uncertain causal origin side
effect that clinicians should be aware of in current regulatory
agency recommendations.(43) More recent data cast doubt on
this understanding. A recent trial of similar design to the HORI-
ZON trial specifically enrolled 2000 women in the osteopenic
range (that is, having a BMD T-score between 2.5 and 1.0).
In a secondary publication of prespecified safety data, Reid and
colleagues(32,33) demonstrated similar event rates for any atrial
fibrillation 14.8 (95% CI, 11.9 to 18.3) events per 1000 zoledronic
acid treated and 15.6 (95% CI, 12.6 to 19.1) events per 1000 pla-
cebo-treated women. The crude event rates were much larger
than HORIZON for both all atrial fibrillation events (8.8% versus
9.5%; RR = 0.95; 95% CI, 0.72 to 1.26) and for number of women
with at least one episode of atrial fibrillation (5.4% versus 5.5%;
RR = 0.98; 95% CI, 0.68 to 1.41). In comparing HORIZON with
the more recent trial in patients with osteopenia, it may be
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argued that the women with osteopenia have a lesser underly-
ing CV disease burden (given the shared underlying risk factors
for both CV disease and osteoporosis), and thus the administra-
tion of zoledronic acid was not sufficient to provoke paroxysms.
Cohort studies have demonstrated inconsistent findings regard-
ing this pre-presumptive association and thus continual investi-
gation and post-market monitoring is prudent.(44)
Zoledronic acid may reduce the risk of myocardial infarction
Contrary to the history of zoledronic acid and atrial fibrillation,
rates of myocardial infarction have not been shown to be
increased with zoledronic acid treatment. In the abovemen-
tioned trial by Reid and colleagues,(32,33) osteopenic women
experienced no increased rate of myocardial infarction, and
indeed may even have experienced a reduced rate of infarcts
(39 [3.9%] versus 43 [4.3%]; RR = 0.58; 95% CI, 0.35 to 0.94). Sur-
vival analysis demonstrated a potential 40% improved survival in
zoledronic acid–treated women (HR= 0.60; 95% CI, 0.36 to 1.00)
was shown, where the survival curves began to deviate at
approximately 18 months.(32,33) These data, although prespeci-
fied, were secondary endpoints and thus warrant interpretation
with caution. This effect is another point of difference between
the trial by Black and colleagues(31) in women with osteoporosis.
There were fewer myocardial infarction events in zoledronic
acid–treated women (38 [1.0%] versus 45 [1.2%]), but this did
not reach statistical significance (RR = 0.84; 95% CI, 0.54 to
1.29). Similar to effects on overall mortality, these data may indi-
cate that BP may exhibit some transient effect which is support
by cohort data on medication adherence. Furthermore, given
the potential action of BP on the cholesterol synthesis pathway,
there is biological rationale to support an effect on ASVD. Further
data are needed to understand if the background ASVD is impor-
tant in determining CV effects on BPs or if indeed BPs have
clinically significant effects in reversing ASVD as per statins.
Abdominal aortic calcification (AAC) is recognized to be a surro-
gate indicator of ASVD and indeed predicts CV and non-CV out-
comes.(15,45–47) In an exploratory substudy of the HORIZON-PFT,
progression of AAC was examined following 3 years of treat-
ment. AAC progression (defined as a change in semiquantitative
AAC score) was similar between treatment groups (67/234
[28.6%] in zoledronic acid–treated versus 82/268 [30.6%] in
placebo-treated; odds ratio [OR] = 0.90; 95% CI, 0.6 to 1.3).(48)
This did not differ by baseline AAC score, nor did change in total
hip (r = 0.02, p = 0.66) or femoral neck BMD (r = 0.03,
p = 0.54) correlate with AAC change. This overall suggests
against a link between the skeleton and calcification in the vas-
culature as a potential mechanism explaining CV benefits or
harms of BPs. However, it should be noted that the semiquanti-
tative AAC scale (0 to 8) may not be sensitive enough to detect
changes over the follow-up period and the intraobserver fidelity
was moderate (0.62). Studies using more sensitive techniques
and scoring systems may yet observe differences. Understand-
ing subtle changes in AAC is important as it remains to be seen
if an AAC score of 0 has similar prognostic power as a coronary
artery calcium score of 0.(49,50)
Oral bisphosphonates have a good safety profile regarding
CV events
Similar to the seminal trials by Black and colleagues(37) and Liber-
man and colleagues(51) in the clinical development of alendro-
nate, trials of other oral formulations have shown similar CV
effects. In a trial of 1200 postmenopausal women younger than
85 years; oral risedronate either 2.5 mg/day or 5.0 mg/day did
not increase the rate of CV events. Compared to placebo
(38 events [9.3%]), there were fewer events in women treated
with 2.5 mg (30 [7.4%]; RR = 0.78; 95% CI, 0.49 to 1.24) and the


































39/1000 (3.9) 43/1000 (4.3) 0.58 (0.35–0.94)
Kim and colleagues(35) (2016) Meta-analysis 69/6154 (1.1) 68/5906 (1.1) 0.96 (0.69–1.34)









20/1000 (2.0) 22/1000 (2.2) 0.90 (0.49–1.66)












71/1000 (7.1) 98/1000 (9.8) 0.72 (0.54–0.97)
Kranenburg and colleagues(36)
(2016)
Meta-analysis 1054/12582 (8.3) 678/9338 (7.2) 1.03 (0.91–1.17)
CAE = cardiovascular adverse event.
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same event rate in women treated with 5.0 mg (38 [9.3%];
RR = 1.00; 95% CI, 0.65 to 1.24). When compared head-to-head
there was a nonsignificant increased rate of events in those trea-
ted with the higher dose (RR = 1.27; 95% CI, 0.80 to 2.01), which
suggests against a dose-response effect.(52)
Denosumab has null effects on CV events
Denosumab is a fully human monoclonal antibody against the
receptor activator of nuclear factor-κB ligand (RANKL), which
exerts potent antiresorptive effects. The largest trial conducted
in the clinical development of denosumab was the Fracture
Reduction Evaluation of Denosumab in Osteoporosis Every
6 Months (FREEDOM) study.(30) This double-blind, placebo-
controlled trial enrolled 7808 postmenopausal women aged
60 to 90 years. Prespecified safety data included serious CV
events, strokes, and coronary heart disease. Analysis of these sec-
ondary endpoints demonstrated no statistical difference in
event rates between the treatment groups (Table 3). For all seri-
ous CV events (186 [4.8%] versus 178 [4.6%]; RR = 1.04; 95% CI,
0.85 to 1.27) and strokes (56 [1.4%] versus 54 [1.4%]; RR = 1.03;
95% CI, 0.71 to 1.49) there was a balance in event rates; whereas
there was a nonstatistically significant reduced event rate in
terms of coronary heart disease (47 [1.2%] versus 39 [1.0%];
RR = 0.87; 95% CI, 0.59 to 1.28). These data are supported by a
series of meta-analyses.(55–57) Similar to the HORIZON substudy
on AAC, RANKL inhibition appeared to not change the fate of
AAC progression in a substudy of the FREEDOM trial (118/544
[22%] in denosumab versus 109/501 [22%] in placebo). This find-
ing was consistent across baseline AAC status (score ≤6 versus
score >6) and, importantly, renal function (estimated glomerular
filtration rate ≤45 versus >45).(58) Again, this supports a view that
a mechanism independent of calcium handling may explain the
benefits or harms of antiresorptive therapies.
Parathyroid hormone analogues have null effects on CV events
Parathyroid hormone (PTH) stimulates bone resorption physio-
logically in order to maintain appropriate circulating calcium
levels. However, the osteoclasts responsible for bone resorption
release chemokines and other hormones that eventually pro-
mote thematuration of osteoblasts resulting in increases in bone
formation. This apparent paradoxical effect is utilized clinically,
where synthetic analogues of PTH such teriparatide (PTH 1–34,
the first 34 amino acids of the hormone) and abaloparatide
(PTH-related protein analogue) are the chief anabolic agents in
the physician’s armamentarium. In terms of CV safety, the key
trial in the clinical development of teriparatide by Neer and col-
leagues in 2001,(59) reported a near balance of cardiac arrhyth-
mias (9/1082 [0.8%] teriparatide-treated versus 12/1088 [1.1%]
placebo-treated; RR = 0.75; 95% CI, 0.31 to 1.78) and no reports
of CV mortality, strokes, ischemic events, or other CV-related
endpoints.(59) Abaloparatide is a peptide that selectively binds
to the RG conformation of the PTH type-1 receptor and is
hypothesized to have greater skeletal effects than teriparatide.
In the pivotal trial for its clinical development over 2400 post-
menopausal women were randomized to either abaloparatide,
teriparatide, or placebo for 18 months. In the safety analysis,
there were similar events rates compared to placebo for the end-
points of myocardial infarction (1/822 [0.12%] abaloparatide-
treated versus 2/820 [0.24%] placebo-treated]; stroke (3/820
[0.37%] versus 0/822 [0.00%]) and atrial fibrillation (0/820
[0.00%] versus 0/822 [0.00%]), which was similar to the experi-
ence with teriparatide two decades earlier.(60) Interestingly, in
the majority of trials, the direction of effect supports a notion
of CV risk reduction, which indirectly supports the underlying
theory of skeletal health being linked to CV health (Table 4).
Romosozumab may increase the risk of ischemic events
Romosozumab is a monoclonal antibody that binds and inhibits
sclerostin, with a dual effect of increasing bone formation and
decreasing bone resorption. In a trial of romosozumab against
placebo, the Fracture Study in Postmenopausal Women with
Osteoporosis (FRAME) trial (3600 postmenopausal women
each arm), there was no imbalance in the number of adjudicated
serious CV events (44 [1.2%] in romosozumab-treated versus
41 [1.1%] in placebo-treated (RR = 1.07; 95% CI, 0.70 to 1.63).
Similarly, there was no imbalance in the number of adjudicated
CV deaths (17 [0.5%] versus 15 [0.5%]; RR = 1.13; 95% CI, 0.56
to 2.26).(62) In contrast, in a similar trial of romosozumab against
placebo in older men (n = 245), the BRIDGE trial, there was a
nonstatistically significant imbalance in adjudicated serious CV
events (8/163 [4.9%] in romosozumab-treated versus 2/81





N (%) RR (95% CI)
Atrial fibrillation Cummings and colleagues(30)
FREEDOM (2009)
Placebo 29/3886 (0.7) 29/3876 (0.7) 0.99 (0.59–1.66)





Placebo 47/3886 (1.2) 39/3876 (1.0) 0.87 (0.59–1.28)
Brown and colleagues(53) (2009) Alendronate 1/593 (0.1) 3/586 (0.5) 0.32 (0.03–3.15)
Stroke Cummings and colleagues(30)
FREEDOM (2009)
Placebo 56/3886 (1.4) 54/3876 (1.3) 1.03 (0.71–1.49)





Placebo 186/3886 (4.8) 178/3876 (4.6) 1.04 (0.85–1.27)
Roux and colleagues(54) (2014) Risedronate 6/429 (1.3) 4/429 (1.0) 1.52 (0.43–5.37)
Seeto and colleagues(55) (2021) Placebo 439/4725 (9.3) 399/4467 (8.9) 1.09 (0.95–1.23)
Seeto and colleagues(55) (2021) Bisphosphonate 85/2136 (3.9) 58/2131 (2.7) 1.46 (1.05–2.02)
CAE = cardiovascular adverse event; n/e = not estimable.
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[2.5%] placebo-treated; RR = 1.98; 95% CI, 0.43 to 9.14). This
imbalance appeared to be driven by an increase in cardiac ische-
mic (3/163 (1.8%) versus 0/81 [0.00%]) and cerebrovascular
events (3/163 [1.8%] versus 1/81 [1.2%]).(63) This small signal
was also evident in the active-controlled trial in postmenopausal
women, the ARCH trial. The comparator in this trial of over 4000
(2000 in each arm) postmenopausal women was oral alendro-
nate. The number of adjudicated serious CV events was higher in
those treated with romosozumab for the first 12 months com-
pared to alendronate (50 [2.5%] versus 38 [1.9%]; RR = 1.29;
95% CI, 0.85 to 1.97). Again, this imbalance seemed to be driven
by ischemic events as there were more myocardial infarctions
(16 [0.8%] versus 6 [0.3%]; RR = 2.25; 95% CI, 0.93 to 5.47) and
strokes (16 [0.8%] versus 7 [0.3%]; RR = 2.25; 95% CI, 0.93 to
5.47), though neither reached statistical significance. There was
no imbalance in the number of CV deaths (17 [0.8%] versus 12
[0.6%]; RR = 1.39; 95% CI, 0.66 to 2.92).(18) Of note, participants
in the ARCH trial included the highest proportion of patients with
a previous history of CV disease 73%, compared to 66% and 65%,
in Placebo-Controlled Study Evaluating the Efficacy and Safety of
Romosozumab in Treating Men With Osteoporosis (BRIDGE) and
FRAME, respectively. Thus, it has been suggested that perhaps
the drug treatment has exacerbated (or provoked) already
underlying CV disease and thus a black box warning for romoso-
zumab is in place for any patient who has experienced a major
CV event.(64–66) This position is not supported by recent a
meta-analysis, where romosozumab was not shown to increase
the risk of a composite cardiovascular outcome of stroke, coro-
nary artery disease, heart failure, and atrial fibrillation
(RR = 1.26; 95% CI, 0.95 to 1.68) or a three-point major adverse
cardiovascular event (MACE) outcome (RR = 1.41; 95% CI, 0.99
to 2.02). However, the lower bounds of the CIs in these estimates
cannot exclude a statistically or clinically important effect, that is
to say the lower bounds of the CIs only just cross unity; therefore,
the majority of the effect lies in the positive direct (namely more
events meaning romosozumab is associated with relative harm).
Interestingly, there was an increase in a four-point MACE
outcome (RR = 1.39; 95% CI, 1.01 to 1.90). This suggests that
assessing CV risks of romosozumab is limited by power (given
that a four-point outcome includes more events than a three-
point outcome). Therefore an event-driven analysis and ongoing
postmarketing analysis should be considered.(56)
Emerging topics in the cardiovascular effects of
antifracture medications
Differential arrhythmic and atherogenic effects of oral and
intravenous bisphosphonates?
Meta-analyses have proven largely unhelpful in clarifying the
potential harmful and/or beneficial effects of bisphosphonates
on cardiovascular outcomes.(35,36,67–69) There exists much varia-
tion in analysis approach (any versus specific BP), included litera-
ture (RCTs, industry sponsored only studies, cohort studies, and
case-control studies) and outcomes. Collectively, the message is
unclear. In the case of drugs with extensive experience, such as
BPs with over 50 years of clinical use, real-world evidence can
complement RCT evidence.(70) There could be several reasons
why many RCTs of BPs on CV outcomes have not provided firm
conclusions. For example, the trials may be underpowered to
detect an adequate number of events, the trial being too short
(again a question of being event-driven) and population charac-
teristics (did the patients have too severe CV disease to benefit
from mild risk reduction or too mild a disease so not enough
events occur over follow-up). Recent real-world evidence for CV
effects of BPs appear to indicate cardioprotection and possibly a
signal toward differential atherogenic and arrhythmic effects. In
a cohort of individuals undergoing bone density testing (clinically
matched on indication), oral BP (96% alendronate) use was associ-
ated with a reduction in atrial fibrillation, heart failure, and stroke
but not myocardial infarction.(71) Small experimental studies in
humans have emerged attempting to define the mechanism
for this demonstrating acute QT effects on electrocardiography
(ECG) following zoledronic acid infusion.(72) However, thismay just
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be a feature of the autonomic response to an infusion. Further to
differential atherogenic and arrhythmic effects, other cohort stud-
ies indicate theremay be differential oral and iv effects of BPs, with
the iv zoledronic acid associated with greater harms than oral
BPs.(44) This is supported by a meta-analysis of the pivotal RCTs
for ibandronate, which showed that although ibandronate was
deemed to be safe overall, there was a greater crude rate of atrial
fibrillation events in patients receiving intravenous ibandronate
(0.5%) compared to the oral formulation (0.3%).(73)
Denosumab safety may support the cardioprotective
hypothesis of BPs
The context of intense CV scrutiny of romosozumab and BPs was
the scientific motivation to reanalyze the specific CV safety data
of denosumab. Two previous meta-analyses have reported on
the CV safety of denosumab, but findings were limited, including
omission of the pivotal trial in the clinical development of deno-
sumab that reported CV safety.(56) In patients with osteoporosis,
it was revealed that compared to placebo (an analysis almost
entirely dominated by the FREEDOM trial), there was no differ-
ence in rates of CV events (RR = 0.79; 95% CI, 0.41 to 1.52). How-
ever, when compared to any BP control, there was a 46%
increased risk of CV events in denosumab-treated women
(RR = 1.46; 95% CI, 1.05 to 2.02). There was a doubling of risk
when considering a five-point MACE outcome (RR = 2.33; 95%
CI, 1.19 to 4.56).(55) These findings mirror what was evidenced
by the romosozumab trials—namely treatment arms experienc-
ing elevated CV events in a BP-controlled trial but not in a
placebo-controlled trial. This provides indirect evidence for car-
dioprotection by BPs. Furthermore, recent studies in postmeno-
pausal women suggest that RANKL inhibition does not alter
markers of ASVD, further supportive of the imbalance of events
seen in the meta-analysis being attributable to suppression of
events in BP arms.(74) Of note, the meta-analysis did not perform
sensitivity analyses for BP type to elucidate if effects were spe-
cific to oral or iv formulations, so direct comparisons to the zole-
dronic acid trials are limited. This is particularly relevant given
that the MACE outcome only reached significance upon inclu-
sion of atrial fibrillation an outcome for which zoledronic acid
has perceived effects.
PTH-analogues may have autonomic heart rate effects of
clinical importance
At the request of the FDA, investigators of the “Abaloparatide
Comparator Trial in Vertebral Endpoints” (ACTIVE) study per-
formed a comprehensive post hoc cardiovascular safety study
of trial participants.(75) Heart rates, blood pressure, and adverse
events presumed related to increased heart rates were recorded.
Overall rates of treatment-emergent adverse events were higher
in participants receiving study medications as expected. How-
ever, treatment-emergent adverse events related to elevated
heart rates that lead to trial discontinuation were substantially
more frequent in abaloparatide-treated (27/822; 3.3%) and
teriparatide-treated (11/818; 1.3%) than placebo (5/820; 0.6%).
By contrast, unadjudicated MACE was approximately half as fre-
quent in abaloparatide (4/822; 0.5%) and teriparatide (5/818;
0.6%) compared to placebo (14/820; 1.7%), representing hazard
reductions of 57% (0.43; 95% CI, 0.13 to 1.34) in abaloparatide-
treated and 51% (0.49; 95% CI, 0.17 to 1.44) in teriparatide-trea-
ted. In a long-term follow-up to these participants, where all par-
ticipants went on to receive alendronate from study months
19 to 42, there was no imbalance in events (7/533 [1.3%] versus
7/580 [1.2%]; HR = 0.67; 95% CI, 0.31 to 1.43). These represent
the most in-depth, published data from RCT participants on
direct cardiac effects of osteoporosis medications. Although haz-
ard reductions were nonsignificant, given PTH analogues are
anabolic, this trial provides indirect evidence to support the the-
ory that bone health has an inverse relationship with cardiac
health.
Ongoing uncertainty of the cardiovascular significance of
romosozumab
There has been substantial interest in understanding if sclerostin
inhibition imposes CV risk since the publication of the ARCH trial
(Table 5). This was recently reviewed briefly by Langdahl and col-
leagues(76) and Fixen and Tunoa.(77) Both reviews concluded
romosozumab to be safe in this respect and warned against
overinterpreting low event rates. There is biological rationale
for why this may be the case. In a murine model of atherosclero-
sis, the SOST gene (which encodes sclerostin) was expressed in
the aorta and upregulation of SOST conferred vasculoprotec-
tion.(78) This finding supports the clinical experience of patients
with sclerosteosis, a genetic mutation leading to the overexpres-
sion of the SOST gene and thus exhibit naturally high levels of
sclerostin. These people exhibit marked bone deposition, but
importantly, appear to be at no increased risk of CV disease.(79)
This would seem at odds with a uniquely designed genetic anal-
ysis of single nucleotide polymorphisms (SNPs) of the SOST gene
associated with increased BMD from several large population
databases. This analysis revealed at least one SNP that imposed
an elevated CV risk, particularly for myocardial infarction and cor-
onary revascularization.(80) This finding would support the black-
Table 5. Cardiovascular Outcomes in the Seminal Romosozumab RCTs
Trial Romosozumab n/N (%) Control n/N (%) RR (95% CI)
FRAME(62) (versus placebo) - All 44/3581 (1.2) 41/3575 (1.1) 1.07 (0.70–1.63)
Ischemic events 2 (0.05) 2 (0.05) 0.99 (0.14–7.08)
Cerebrovascular events 8 (0.22) 9 (0.25) 0.88 (0.34–2.29)
ARCH(18) (versus alendronate) - All 50/2040 (2.5) 38/2014 (1.9) 1.29 (0.85–1.97)
Ischemic events 16 (0.8) 6 (0.3) 2.63 (1.03–6.71)
Cerebrovascular events 16 (0.8) 7 (0.3) 2.25 (0.93–5.47)
BRIDGE(63) (versus placebo) - All 8/163 (4.9) 2/81 (2.5) 1.98 (0.43–9.14)
Ischemic events 3 (1.8) 0 (0.0) n/e
Cerebrovascular events 3 (1.8) 1 (1.2) 1.49 (0.15–14.11)
Bold values signifies statistically significant.
n/e = not estimable.
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box warning by the FDA. However, when considered in the con-
text of myocardial infarction risk reduction in the zoledronate
trial of osteopenic women, suggestive of cardioprotection by
BPs, these data provide a compelling research justification an
RCT with a vascular primary outcome. Presently, it is still uncom-
fortably uncertain if the romosozumab increases CV events or
BPs suppress CV events.
The Future
In the big data age, it is becoming easier to investigate in a rapid
and high throughout manner, “off-target” effects of common
medications, albeit not without the risk of confounding. There
is a business case for this; most drugs have a finite lifespan under
patent so the window for pharmaceutical companies to finan-
cially exploit their invention is limited. Repurposing of existing
medications known to be safe by expanding the indication thus
has enormous attraction. A recent success story of this has been
the CV efficacy of sodium-glucose co-transporter 2 inhibitors in
patients without diabetes.(81) Equally, from a public health stand-
point there is merit in looking for and confirming putative “off-
target” effects. Many osteoporosis medications, particularly alen-
dronate, are currently available as a generic. Thus, if a genuine
“off-target” effect is established (that is to say, demonstrated in
an adequately powered RCT) and regulatory authorities grant
an expanded indication, this could potentially save healthcare
systems a significant amount of money. This is already happen-
ing, one example being ticagrelor. Originally marketed as an
anti-platelet agent for the treatment and prevention of stroke
and coronary outcomes, the pivotal efficacy trial demonstrated
reduced pulmonary events, and this has been followed up with
studies demonstrating antimicrobial properties.(82–84) The natu-
ral endpoint of repurposing is eventual incorporation into the
approval process. There is precedent for this, as new agents for
diabetes must now demonstrate safety as well as CV efficacy.
One may argue that the links between bone disease and CV dis-
ease is just as strong as that between diabetes and CV disease.
Thus, given the risk of CV outcomes imposed by osteoporosis
and the high ASVD burden in this population, there can be an
argument for this to also occur for new skeletal agents. The expe-
rience of romosozumab shows that the field seeks this evidence;
and it would bewiser to have this data produced in the setting of
a large, well-designed RCT rather than relying on the eventual
churn of reviews and subpar meta-analyses. Such large, well-
designed RCTs are near prohibitively expensive and pharmaceu-
tical companies are likely to resist subjecting their novel agents
to this scrutiny. Thus, there is a role for well-designed cohort
studies to provide real-world evidence and work in tandem with
RCTs.(85,86)
Conclusion and Research Agenda
The literature examining the potential CV harms or benefits of
antifracture medications is now quite substantial. This is helped
by more rigorous reporting, where registered trials are required
to report adverse drug reactions (ADRs). The systematic collec-
tion of ADRs both in trials and population-wide health systems
through electronic medical records and claims databases means
that the body of real-world evidence is substantial. Generally,
these findings have been complimentary to findings in RCTs.
However, this has not led to firm conclusions. First, adverse event
reporting from RCTs means that the majority of evidence on this
topic is secondary and subject to bias and being underpowered.
Meta-analyses, in an attempt to overcome the issue of power,
have largely proved unhelpful and are often poorly conducted.
By way of example, a meta-analysis of PTH-analogues included
the pivotal trial by Neer and colleagues.(59) This trial was
included in summary estimates despite not reporting specific
CV events in the primary publication nor are data available
on the trial’s registration page. Not reporting events does not
necessarily mean zero events.
The overarching question of the CV safety for antifracture
medications can only definitively be answered in an RCT. There
is particular need for an RCT of BPs with a primary vascular end-
point in order to allay criticism that interpretation of safety data
needs to be cautious. Further, such an RCT needs to be event-
driven to avoid overinterpretation of low event rates. There
may be an ethical concern for conducting such a trial of “repur-
posing” a medication. Is it justified to apply a medication to
examine an “off-target” effect if proven treatments for those
“off-target” effects already exist? However, patients with osteo-
porosis have a high ASVD burden and likely other adverse risk
markers so the balance of benefit and harm may fall marginally
in favor of the trial. Overall, there is need to optimize CVmanage-
ment for improved skeletal outcomes. Furthermore, there is
need to better understand the clinical and biological links
between skeletal and CV disease because antifracture medica-
tions appear to have no effect on aortic calcification (a robust
marker of both skeletal and CV risks).(48,58) Therefore, exploring
other mechanisms such as potential electrophysical effects,
antithrombotic effects, effects on autonomic function after iv
infusion, or plaque stabilization effects may offer a window into
the bone-vascular axis. In conclusion, the clinical message should
be that osteoporosis medications have a very good safety record
and that there is a clear research need to study the potential CV
benefits that may, perhaps surprisingly, accompany restoration
of bone health.(71,87,88)
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